Table 8.
Patients data in the validation group
| Parameter | No adverse reactions (n=94) | Adverse reactions (n=33) | t/χ2 | P |
|---|---|---|---|---|
| Age (years) | 57.68 ± 3.18 | 58.91 ± 4.09 | 1.568 | 0.124 |
| Gender (M/F) | 52 (55.32%)/42 (44.68%) | 14 (42.42%)/19 (57.58%) | 1.151 | 0.283 |
| Body mass index (kg/m2) | 22.19 ± 2.83 | 22.67 ± 1.38 | 1.259 | 0.211 |
| Smoking history | 18 (19.15%)/76 (80.85%) | 5 (15.15%)/28 (84.85%) | 0.063 | 0.802 |
| Drinking history | 15 (15.96%)/79 (84.04%) | 6 (18.18%)/27 (81.82%) | 0.001 | 0.981 |
| Comorbidities (%) | ||||
| Hypertension | 11 (11.7%) | 5 (15.15%) | 0.044 | 0.835 |
| Diabetes | 15 (15.96%) | 6 (18.18%) | 0.001 | 0.981 |
| ECOG performance status | 0.009 | 0.923 | ||
| 0 | 37 (39.36%) | 12 (36.36%) | ||
| 1 | 57 (60.64%) | 21 (63.64%) | ||
| Family history of cancer | 24 (25.53%) | 7 (21.21%) | 0.068 | 0.794 |
| History of CNS involvement | 32 (34.04%) | 9 (27.27%) | 0.249 | 0.618 |
| Liver metastasis | 18 (19.15%) | 5 (15.15%) | 0.063 | 0.802 |
| Histology | 0.285 | 0.594 | ||
| Squamous | 2 (2.13%) | 2 (6.06%) | ||
| Non-squamous | 92 (97.87%) | 31 (93.94%) | ||
| Disease stage | 0.003 | 0.955 | ||
| Locally advanced and unresectable | 5 (5.32%) | 1 (3.03%) | ||
| Metastatic | 89 (94.68%) | 32 (96.97%) | ||
| LCP1 Expression (mRNA) | 2.28 ± 0.36 | 2.48 ± 0.43 | 2.416 | 0.020 |
| ADPGK Expression (mRNA) | 1.89 ± 0.69 | 2.31 ± 0.78 | 2.733 | 0.009 |
| LCP1 Protein Level | 1.16 ± 0.24 | 1.29 ± 0.26 | 2.398 | 0.020 |
| ADPGK Protein Level | 0.97 ± 0.21 | 1.07 ± 0.22 | 2.338 | 0.023 |
Note: ECOG: Eastern Cooperative Oncology Group; LCP1: Leukocyte-specific protein 1; ADPGK: adenosine diphosphate-dependent glucokinase; mRNA: Messenger Ribonucleic Acid.